Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

77.20 USD +0.55 (+0.71%)
Streaming Delayed Price Updated: 12:26 PM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Clinical Trials for Evolving Targeted Therapies Fueling Gains for Brain Tumor Therapeutics Market
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Clinical Trials for Evolving Targeted Therapies Fueling Gains for Brain Tumor Therapeutics Market
Financialnewsmedia.com News Commentary 
From PR Newswire
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews 
From Business Wire News Releases
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymph
FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma 
From Business Wire News Releases
Merck Announces Appointment of Organon & Co. General Counsel
Merck Announces Appointment of Organon & Co. General Counsel 
From Business Wire News Releases
LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer 
From Business Wire News Releases
Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Merck and Eisai Receive Complete Response Letter for KEYTRUDA plus LENVIMA as First-Line Treatment for Unresectable Hepatocellular Carcinoma 
From Business Wire News Releases
Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
Merck Announces New Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection 
From Business Wire News Releases
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals 
From Business Wire News Releases
Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction
Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction 
From Business Wire News Releases
Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31
Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31 
From Business Wire News Releases
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer 
From Business Wire News Releases
Advancements in Breast Cancer Research & Clinical Studies Producing Optimism for New Treatments
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Advancements in Breast Cancer Research & Clinical Studies Producing Optimism for New Treatments
Financialnewsmedia.com News Commentary 
From PR Newswire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
FDA Approves Merck’s KEYTRUDA® for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC). 
From Business Wire News Releases
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual 
From Business Wire News Releases
BioInvent Enrolls First Patient in Phase I/IIa Trial of BI-1206 in Combination With KEYTRUDA® for the Treatment of Patients With Solid Tumors
BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,... 
From PR Newswire
Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults
V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults. 
From Business Wire News Releases
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
KEYTRUDA® Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma 
From Business Wire News Releases
Merck Completes Acquisition of Themis
Merck Completes Acquisition of Themis 
From Business Wire News Releases
Merck Animal Health Completes Acquisition of Quantified Ag®
Merck Animal Health Completes Acquisition of Quantified Ag® 
From Business Wire News Releases
FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type
FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA (pembrolizumab), Regardless of Tumor Type 
From Business Wire News Releases
Merck Prices $4.5 Billion Debt Offering
Merck Prices $4.5 Billion Debt Offering 
From Business Wire News Releases
Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Merck and Pfizer’s SGLT2 Inhibitor STEGLATRO Meets Primary Endpoint in VERTIS CV Trial for Patients with Type2 Diabetes and Atherosclerotic CV Disease 
From Business Wire News Releases
Advanced Devices Give Patients More Flexibility for Managing Their Conditions
FinancialBuzz.com News Commentary 
From PR Newswire
Merck Announces Call for Proposals for Second Cohort of Safer Childbirth Cities, Expanding Maternal Health Support Across US Cities
Merck Announces Call for Proposals for Second Cohort of Safer Childbirth Cities, Expanding Maternal Health Support Across US Cities 
From Business Wire News Releases
FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers
FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers 
From Business Wire News Releases
Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma
Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Urothelial Carcinoma 
From Business Wire News Releases
FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
FDA Approves Merck’s RECARBRIO for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) 
From Business Wire News Releases
LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for First-Line Maintenance Treatment of Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer
LYNPARZA Receives Positive Opinion from EU CHMP for First-Line Maintenance of Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account